SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Britain Courts Anthropic Amid US Defense Department Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
KING OF PRUSSIA, Pa., June 21, 2017 -- Aspire Bariatrics, Inc., a commercial-stage medical device company announced today that it received approval to market the AspireAssist®, a novel device for the treatment of obesity, in Australia by the Therapeutic Goods Administration (TGA) and that the first cases using the AspireAssist have been performed in Australia.
“Until the AspireAssist, the only available option to treat obesity in people with severe obesity has been bariatric surgery. Although effective in weight loss, bariatric surgery is not favored by many patients because of its irreversibility and their concern about complications,” said Dr. Patrick Walsh, BSC, MB CHB, FRACP, of Intensiv Weight Loss of Queensland, Australia. “The AspireAssist provides comparable weight loss to bariatric surgery but is reversible, with few and minor complications.”
“We are pleased to be able to offer the AspireAssist as a treatment option for people with obesity in Australia. Australia has been one of the most forward-thinking countries in the treatment of obesity and we look forward to expanding our presence there,” said Katherine Crothall, PhD, President & CEO of Aspire Bariatrics.
About Aspire Bariatrics, Inc.
Aspire Bariatrics is a commercial-stage medical device company with a minimally-invasive, endoscopic device, the AspireAssist®, to treat obesity. In June 2016, the Company received premarket approval (PMA) from the FDA. AspireAssist Therapy is an alternative to bariatric surgery, providing comparable weight loss, but with far better safety, complete reversibility, and at a significantly lower cost than bariatric surgery. The therapy provides a holistic approach to patient development of improved eating behaviors, reflected in significant improvement in quality of life and high satisfaction with the therapy. www.aspirebariatrics.com.
Contact for Investors and Media Kathy Crothall, PhD President and CEO (610) 590-1568 [email protected]
